KAT6A and ovarian cancer: WM‐1119 decreased the number of metastatic foci and amount of ascites fluid formation in the KAT6A‐ΔIDR group, but WM‐1119 had no effects on the development of KAT6A‐WT ovarian cancer (Figure 4I; Figure S3B, Supporting Information), demonstrating that KAT6A promotes PARPi resistance independent of its catalytic function.